Lee's Pharmaceutical Holdings Limited 0950
HKEX · Hong Kong SAR China · Health Technology
HKD 1.17-0.03 (-2.50%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
1cBio, a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm"), today announced that the companies have entered into a licensing agreement granting Lee's Pharm exclusive rights to develop and commercialize 1cBio's lead PARP1 inhibitor, OC-3, in China and certain countries in Southeast Asia. Under the terms of the agreement, 1cBio
NEW YORK, July 21, 2026--Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience.
As global markets navigate a week marked by volatility and geopolitical tensions, small-cap stocks continue to capture attention with their potential for growth amid fluctuating economic indicators. In this dynamic environment, identifying undiscovered gems requires a keen eye for companies that demonstrate resilience and adaptability, particularly those poised to benefit from shifts in trade policies or emerging market trends.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.